CytoDyn

OTC.QB: CYDY - www.cytodyn.com

Recent Stock Price (1/11/18)	$0.59
52-Week Range	$0.46-$0.84
Market Capitalization	$100.2M
Shares Outstanding	169.9M
Fiscal Year-End	May 31

PRO 140: First self-administered, injectable antibody therapy for HIV in late-stage clinical development

- **PRO 140** is a humanized monoclonal antibody for treating human immunodeficiency virus (HIV)
- CytoDyn is focused on the clinical development and commercialization of PRO 140 with the following trials underway:
  - Phase 2b/3 pivotal trial in combination with the current standard-of-care
  - Phase 2b/3 trial as a long-term monotherapy to replace the current standard-of-care
  - Phase 2b in the extension portion of a completed monotherapy Phase 2b study
- Advantages of PRO 140 over current standard-of-care HAART (Highly Active Antiretroviral Therapy)
  - Minimal toxicity and side effects
  - No resistance observed in patients for more than 2.5 years
  - Ease of compliance – once a week dosing
- Clinical data thus far indicates that PRO 140 significantly reduces viral load and maintains this reduction
- CytoDyn is investigating immunologic indications for PRO 140 supported by positive preclinical studies
  - Transplantations, Graft versus Host Disease (GvHD), cancer, autoimmune diseases (MS)

Executive Management Team

- **Anthony Caracciolo, Executive Chairman**: Former Gilead Senior Vice President of Manufacturing and Operations, member of Gilead executive committee, over 30 years of executive and senior leadership
- **Nader Pourhassan, PhD, CEO**: Led the development path way for PRO 140 and was instrumental in leading the Company through several rounds of financing
- **Michael Mulholland, CFO**: Financial executive with 30 years of senior financial leadership with public companies in several industries. Experienced in strategic planning, corporate finance, and M&A
- **Denis Burger, PhD, Vice Chairman, CSO**: Former academic immunologist, successful biotech CEO, experienced with public company financing. Manages the immunologic indications for PRO 140

Investment Highlights

- **$20 billion U.S. HIV therapeutics market** suffers from difficult dosing schedules, drug resistance, side effects, and toxicity with standard-of-care HAART therapy
- **PRO 140 addresses HAART shortcomings** with no serious side effects, minimal toxicity, and no drug resistance in weekly, self-administered subcutaneous dosing
- **Near-term results of primary endpoint for efficacy from Phase 2b/3 pivotal trial** as a combination HIV therapy with Fast-Track Designation
- **Investigative Phase 2b/3 monotherapy trial initiated** for HIV as long-term monotherapy with the first patients injected in late 2016. Provides safety data for pivotal trial
- **Phase 2 trial in GvHD with FDA Orphan Drug Designation,** with further pipeline opportunities in cancer and autoimmune disease

PRO 140 Important Milestones 2017/2018	Target Dates
HIV Fast Track Designation	Granted
HIV Breakthrough Therapy Designation (BTD)	2018
CD02 Pivotal Phase 2b/3 HIV Combination Trial Primary Endpoint	1Q 2018
CD02 HIV Combination Therapy BLA Submission, with BTD	2018
CD02 HIV Combination Therapy Approval	2019 w/BTD
Published Studies – HIV; GvHD	Completed
Orphan Drug Designation for GvHD	FDA Granted
Medical Conference Presentations (CROI and ASM Microbe)	Completed
CD03 Phase 2b/3 Monotherapy Investigative Trial Readout	2018

About PRO 140

PRO 140 belongs to a new class of HIV/AIDS therapeutics called viral-entry inhibitors, which are intended to protect healthy cells from viral infection. Importantly, PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 does not activate CCR5 expressing cells, but does limit their participation in inflammatory diseases (GvHD, autoimmunity).

The information contained herein was obtained from the management of CytoDyn Inc. and other sources LHA believes to be reliable. LHA is engaged by CytoDyn as its investor relations firm. This document contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. Statements in this document, which are not a plain recitation of fact should be considered forward-looking statements. This document shall not constitute an offer to sell, or the solicitation of an offer, to buy or sell securities. Risks relating to CytoDyn and its business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this document, are detailed in CytoDyn's latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this document speak only as of this date, and CytoDyn disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law. January 2018

Contact:

At the Company
Dr. Denis Burger, CSO
360-980-8524

Investors
LHA – Jody Cain
Jcain@lhai.com
310-691-7100